ArticleADMET & DMPK2025
A simple UiO-66-NH
Article in ADMET & DMPK, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Highly sensitive voltammetric determination of Pb²⁺ and Cd²⁺ ions using a carbon paste electrode modified with Mn₀.₅Zn₀.₅Fe₂O₄ spinel ferrite nanoparticles.Scientific reports · 2026Article
- Surfactant/β-cyclodextrin inclusion-mediated nucleic acid enrichment for ratiometric electrochemical sensing of low-abundance Staphylococcus aureus.Mikrochimica acta · 2026Article
- Mechanistic pseudo-two-dimensional modeling of redox-mediated electrochemical reduction of metronidazole at cobalt oxide nanostructured electrodes.RSC advances · 2026Article
- Synthesis and characterization of bimetallic nanocomplex: Application for electrochemical determination of idarubicin as anti-cancer drug.ADMET & DMPK · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Metronidazole (MRNZ) is a highly efficacious pharmacological agent for treating protozoal infections, including trichomoniasis, giardiasis, and disorders caused by anaerobic bacteria. Experimental approach: In the present investigation, a solvothermal approach is employed to synthesize a composite of multiwalled carbon nanotubes (MWCNTs-COOH) with UiO-66-NH Key results: Under optimal experimental conditions, the developed electrochemical sensor exhibited outstanding metrics of repeatability, stability, selectivity, and reproducibility for detection across an extensive concentration range, specifically from 0.5 to 350.0 μM, while achieving a limit of detection of 0.1 μM. Furthermore, the practical application of the sensor was rigorously assessed using MRNZ tablet samples and urine specimens, resulting in a commendable recovery rate of MRNZ, ranging from 97.3 to 104.0 %. Conclusion: This research elucidates a straightforward, expedited, and significant methodology for the application of UiO-66-NH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.